

Klaus Seppi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/719223/publications.pdf>

Version: 2024-02-01

289
papers

23,326
citations

8749

75
h-index

9854

141
g-index

298
all docs

298
docs citations

298
times ranked

19369
citing authors

#	ARTICLE	IF	CITATIONS
1	Symptomatic Care in Multiple System Atrophy: State of the Art. <i>Cerebellum</i> , 2023, 22, 433-446.	1.4	7
2	Factors associated with impaired quality of life three months after being diagnosed with COVID-19. <i>Quality of Life Research</i> , 2022, 31, 1401-1414.	1.5	18
3	Clia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [¹¹ C]PBR28 and Machine Learning Analysis. <i>Movement Disorders</i> , 2022, 37, 119-129.	2.2	18
4	Pragmatic Approach on Neuroimaging Techniques for the Differential Diagnosis of Parkinsonisms. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 6-19.	0.8	21
5	An MDS Evidence-Based Review on Treatments for Huntington's Disease. <i>Movement Disorders</i> , 2022, 37, 25-35.	2.2	19
6	Association of Essential Tremor With Novel Risk Loci. <i>JAMA Neurology</i> , 2022, 79, 185.	4.5	17
7	Cardiac sympathetic innervation in Parkinson's disease versus multiple system atrophy. <i>Clinical Autonomic Research</i> , 2022, 32, 103-114.	1.4	7
8	Differentiating Parkinson's Disease from Essential Tremor Using Transcranial Sonography: A Systematic Review and Meta-Analysis. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1115-1123.	1.5	7
9	Prodromal Parkinson's disease: hype or hope for disease-modification trials?. <i>Translational Neurodegeneration</i> , 2022, 11, 11.	3.6	21
10	Sensitivity to Change and Patient-Centricity of the Unified Multiple System Atrophy Rating Scale Items: A Data-Driven Analysis. <i>Movement Disorders</i> , 2022, 37, 1425-1431.	2.2	8
11	Synonymous mutation in adenosine triphosphatase copper-transporting beta causes enhanced exon skipping in Wilson disease. <i>Hepatology Communications</i> , 2022, 6, 1611-1619.	2.0	6
12	Undetected ophthalmological disorders in Parkinson's disease. <i>Journal of Neurology</i> , 2022, 269, 3821-3832.	1.8	11
13	Neurological outcomes 1 year after COVID-19 diagnosis: A prospective longitudinal cohort study. <i>European Journal of Neurology</i> , 2022, 29, 1685-1696.	1.7	57
14	Associations of Gait Disorders and Recurrent Falls in Older People: A Prospective Population-Based Study. <i>Gerontology</i> , 2022, 68, 1139-1144.	1.4	3
15	Factors associated with augmentation in patients with restless legs syndrome. <i>European Journal of Neurology</i> , 2022, 29, 1227-1231.	1.7	1
16	Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy/Parkinsonism From Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 1272-1281.	2.2	17
17	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 1131-1148.	2.2	222
18	Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1369-1387.	1.5	10

#	ARTICLE	IF	CITATIONS
19	Effects of Nabilone on Sleep Outcomes in Patients with Parkinson's Disease: A Posthoc Analysis of the NMS Nab Study. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 751-758.	0.8	10
20	Eye Tracking in Patients with Parkinson's Disease Treated with Nabilone—Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study. <i>Brain Sciences</i> , 2022, 12, 661.	1.1	4
21	Intercountry comparisons of advanced Parkinson's disease symptoms and management: Analysis from the OBSERVE-PD observational study. <i>Acta Neurologica Scandinavica</i> , 2022, 146, 167-176.	1.0	3
22	Disease Progression in Multiple System Atrophy—Novel Modeling Framework and Predictive Factors. <i>Movement Disorders</i> , 2022, 37, 1719-1727.	2.2	7
23	European Academy of Neurology/Movement Disorder Society—European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies. <i>Movement Disorders</i> , 2022, 37, 1360-1374.	2.2	49
24	European Academy of Neurology/Movement Disorder Society—European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies. <i>European Journal of Neurology</i> , 2022, 29, 2580-2595.	1.7	22
25	Characterization and diagnostic potential of R2* in early-stage progressive supranuclear palsy variants. <i>Parkinsonism and Related Disorders</i> , 2022, 101, 43-48.	1.1	5
26	A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study. <i>Movement Disorders</i> , 2021, 36, 681-689.	2.2	22
27	Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 87-91.	1.1	16
28	Automated Analysis of Diffusion-Weighted Magnetic Resonance Imaging for the Differential Diagnosis of Multiple System Atrophy from Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 241-245.	2.2	15
29	Impaired Inhibitory Control of Saccadic Eye Movements in Cervical Dystonia: An Eye-Tracking Study. <i>Movement Disorders</i> , 2021, 36, 1246-1250.	2.2	2
30	Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement. <i>Clinical Autonomic Research</i> , 2021, 31, 157-164.	1.4	22
31	Birds of a Feather Flock Together: Disadvantageous Decision Making in Augmented Restless Legs Syndrome Patients with and without Impulse Control Disorders. <i>Brain Sciences</i> , 2021, 11, 383.	1.1	4
32	Towards subgroup-specific risk estimates: A meta-analysis of longitudinal studies on olfactory dysfunction and risk of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 84, 155-163.	1.1	4
33	Application of the Updated Movement Disorder Society Criteria for Prodromal Parkinson's Disease to a Population-Based 10-Year Study. <i>Movement Disorders</i> , 2021, 36, 1464-1466.	2.2	11
34	Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia are more frequent in advanced versus early Parkinson's disease. <i>Sleep</i> , 2021, 44, .	0.6	16
35	Laboratory-Supported Multiple System Atrophy beyond Autonomic Function Testing and Imaging: A Systematic Review by the MoDiMSA Study Group. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 322-340.	0.8	7
36	Characterization and diagnostic potential of diffusion tractography in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2021, 85, 30-36.	1.1	8

#	ARTICLE	IF	CITATIONS
37	Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder. <i>Brain</i> , 2021, 144, 1118-1126.	3.7	92
38	Speech Biomarkers in Rapid Eye Movement Sleep Behavior Disorder and Parkinson Disease. <i>Annals of Neurology</i> , 2021, 90, 62-75.	2.8	73
39	Neurological outcome and quality of life 3 months after COVID-19: A prospective observational cohort study. <i>European Journal of Neurology</i> , 2021, 28, 3348-3359.	1.7	126
40	Differentiating PSP from MSA using MR planimetric measurements: a systematic review and meta-analysis. <i>Journal of Neural Transmission</i> , 2021, 128, 1497-1505.	1.4	7
41	Automated segmentation of deep brain nuclei using convolutional neural networks and susceptibility weighted imaging. <i>Human Brain Mapping</i> , 2021, 42, 4809-4822.	1.9	10
42	The Parkinson disease connectome – insights from new imaging studies. <i>Nature Reviews Neurology</i> , 2021, 17, 527-528.	4.9	5
43	Urodynamic Evaluation in Multiple System Atrophy: A Retrospective Cohort Study. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1052-1060.	0.8	6
44	Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter?. <i>Movement Disorders</i> , 2021, 36, 2703-2705.	2.2	1
45	Reply to: "Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy". <i>Movement Disorders</i> , 2021, 36, 2208-2209.	2.2	0
46	A Modified Progressive Supranuclear Palsy Rating Scale. <i>Movement Disorders</i> , 2021, 36, 1203-1215.	2.2	13
47	Tit for Tat: Costly Punishment in Manifest Huntington's Disease. <i>Neurodegenerative Diseases</i> , 2021, 21, 74-78.	0.8	1
48	Characterization of gait variability in multiple system atrophy and Parkinson's disease. <i>Journal of Neurology</i> , 2021, 268, 1770-1779.	1.8	18
49	Gait and postural disorders in parkinsonism: a clinical approach. <i>Journal of Neurology</i> , 2020, 267, 3169-3176.	1.8	30
50	Midbrain hyperechogenicity, hyposmia, mild parkinsonian signs and risk for incident Parkinson's disease over 10 years: A prospective population-based study. <i>Parkinsonism and Related Disorders</i> , 2020, 70, 51-54.	1.1	23
51	A Standardized MR Imaging Protocol for Parkinsonism. <i>Movement Disorders</i> , 2020, 35, 1745-1750.	2.2	7
52	Time will tell: Decision making in premanifest and manifest Huntington's disease. <i>Brain and Behavior</i> , 2020, 10, e01843.	1.0	9
53	The Frontal Assessment Battery in RLS patients with and without augmentation. <i>Sleep Medicine</i> , 2020, 75, 456-458.	0.8	4
54	Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone. <i>Annals of Neurology</i> , 2020, 88, 712-722.	2.8	55

#	ARTICLE	IF	CITATIONS
55	Has Deep Brain Stimulation Changed the Very Long-Term Outcome of Parkinson's Disease? A Controlled Longitudinal Study. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 782-787.	0.8	11
56	Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease. <i>Neurology</i> , 2020, 95, e2854-e2865.	1.5	25
57	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 750-762.	0.8	31
58	Augmentation in restless legs syndrome: an eye tracking study on emotion processing. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1620-1627.	1.7	8
59	Application of a Simple Parkinson's Disease Risk Score in a Longitudinal Population-Based Cohort. <i>Movement Disorders</i> , 2020, 35, 1658-1662.	2.2	11
60	Effects of self-administered cannabidiol in a patient with multiple system atrophy. <i>Clinical Autonomic Research</i> , 2020, 30, 355-356.	1.4	6
61	Symptomatic hemiparkinsonism due to extensive middle and posterior fossa arachnoid cyst: case report. <i>BMC Neurology</i> , 2020, 20, 89.	0.8	3
62	Seeing ophthalmologic problems in Parkinson disease. <i>Neurology</i> , 2020, 94, e1539-e1547.	1.5	45
63	Left-hemispheric predominance of nigrostriatal deficit in isolated REM sleep behavior disorder. <i>Neurology</i> , 2020, 94, e1605-e1613.	1.5	23
64	Validation of the Neurogenic Orthostatic Hypotension Ratio with Active Standing. <i>Annals of Neurology</i> , 2020, 88, 643-645.	2.8	27
65	The footprint of orthostatic hypotension in parkinsonian syndromes. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 107-109.	1.1	3
66	Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 57-63.	1.1	18
67	Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study. <i>Movement Disorders</i> , 2020, 35, 976-983.	2.2	38
68	Diagnostic potential of automated tractography in progressive supranuclear palsy variants. <i>Parkinsonism and Related Disorders</i> , 2020, 72, 65-71.	1.1	11
69	Cognition in multiple system atrophy: a single-center cohort study. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 219-228.	1.7	31
70	No effect of age, gender and total intracranial volume on brainstem MR planimetric measurements. <i>European Radiology</i> , 2020, 30, 2802-2808.	2.3	5
71	New hopes for disease modification in Parkinson's Disease. <i>Neuropharmacology</i> , 2020, 171, 108085.	2.0	25
72	Extending the spectrum of non-motor symptoms with olfaction in pre-motor Huntington's disease – a pilot study. <i>Neurodegenerative Diseases</i> , 2020, 20, 207-211.	0.8	1

#	ARTICLE	IF	CITATIONS
73	Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2019, 58, 23-27.	1.1	16
74	Towards seeing the visual impairments in Parkinson's disease: protocol for a multicentre observational, cross-sectional study. <i>BMC Neurology</i> , 2019, 19, 141.	0.8	11
75	Comment: Autologous mesenchymal stem cells. <i>Neurology</i> , 2019, 93, 25-25.	1.5	0
76	Urinary retention discriminates multiple system atrophy from Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1926-1928.	2.2	19
77	Physiotherapy improves motor function in patients with the Parkinson variant of multiple system atrophy: A prospective trial. <i>Parkinsonism and Related Disorders</i> , 2019, 67, 60-65.	1.1	23
78	Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations. <i>CNS Drugs</i> , 2019, 33, 905-918.	2.7	92
79	Diagnostic Potential of Multimodal MRI Markers in Atypical Parkinsonian Disorders. <i>Journal of Parkinson's Disease</i> , 2019, 9, 681-691.	1.5	15
80	Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study. <i>The Lancet Digital Health</i> , 2019, 1, e222-e231.	5.9	73
81	International Guidelines for the Treatment of Huntington's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 710.	1.1	98
82	Nabilone for non-motor symptoms of Parkinson's disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study). <i>Journal of Neural Transmission</i> , 2019, 126, 1061-1072.	1.4	16
83	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984.	2.2	73
84	Morphometric MRI profiles of multiple system atrophy variants and implications for differential diagnosis. <i>Movement Disorders</i> , 2019, 34, 1041-1048.	2.2	36
85	Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 301-309.	1.2	30
86	Characterizing advanced Parkinson's disease: OBSERVE-PD observational study results of 2615 patients. <i>BMC Neurology</i> , 2019, 19, 50.	0.8	74
87	Early distinction of Parkinson's variant multiple system atrophy from Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 440-441.	2.2	21
88	Imaging markers of disease progression in multiple system atrophy. <i>Future Neurology</i> , 2019, 14, FNL24.	0.9	3
89	Multiple system atrophy. <i>International Review of Neurobiology</i> , 2019, 149, 137-192.	0.9	74
90	Prevalence and Associated Factors of Sarcopenia and Frailty in Parkinson's Disease: A Cross-Sectional Study. <i>Gerontology</i> , 2019, 65, 216-228.	1.4	63

#	ARTICLE	IF	CITATIONS
91	Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. <i>Lancet Neurology</i> , The, 2019, 18, 165-176.	4.9	82
92	Update on treatments for nonmotor symptoms of Parkinson's diseaseâ€”an evidenceâ€based medicine review. <i>Movement Disorders</i> , 2019, 34, 180-198.	2.2	619
93	International Parkinson and movement disorder society evidenceâ€based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1248-1266.	2.2	601
94	The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2018, 54, 90-94.	1.1	49
95	The reorganization of functional architecture in the early-stages of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 50, 61-68.	1.1	64
96	Reflection impulsivity perceptual decisionâ€making in patients with restless legs syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 315-322.	1.7	10
97	Diagnostic potential of dentatorubrothalamic tract analysis in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2018, 49, 81-87.	1.1	27
98	Performance of the Movement Disorders Society criteria for prodromal Parkinson's disease: A populationâ€based 10â€year study. <i>Movement Disorders</i> , 2018, 33, 405-413.	2.2	53
99	Relationship between the MDS-LIPDRS and Quality of Life: A large multicenter study of 3206 patients. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 83-89.	1.1	46
100	Cannabinoids for Treatment of Dystonia in Huntingtonâ€™s Disease. <i>Journal of Huntington's Disease</i> , 2018, 7, 167-173.	0.9	33
101	Shaker-related voltage-gated potassium channels Kv1 in human hippocampus. <i>Brain Structure and Function</i> , 2018, 223, 2663-2671.	1.2	4
102	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. <i>Neurology</i> , 2018, 90, 74-82.	1.5	23
103	MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP. <i>Parkinsonism and Related Disorders</i> , 2018, 46, 47-55.	1.1	45
104	The Parkinson's progression markers initiative (PPMI) â€ establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1460-1477.	1.7	330
105	Structural Imaging in Atypical Parkinsonism. <i>International Review of Neurobiology</i> , 2018, 142, 67-148.	0.9	27
106	Diagnosis of PSP-P: Can a newly developed MRPI make the difference?. <i>Parkinsonism and Related Disorders</i> , 2018, 54, 1-2.	1.1	1
107	Reader response: Olfaction and incident Parkinson disease in US white and black older adults. <i>Neurology</i> , 2018, 90, 940-940.	1.5	5
108	Sensorâ€based gait analysis in atypical parkinsonian disorders. <i>Brain and Behavior</i> , 2018, 8, e00977.	1.0	43

#	ARTICLE	IF	CITATIONS
109	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1643-1646.	2.2	114
110	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1601-1608.	2.2	171
111	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 33-40.	1.1	17
112	Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 619-623.	2.2	129
113	Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 536-544.	0.8	65
114	Ocular and visual disorders in Parkinson's disease: Common but frequently overlooked. <i>Parkinsonism and Related Disorders</i> , 2017, 40, 1-10.	1.1	110
115	Letter re: Incident parkinsonism in older adults without Parkinson disease. <i>Neurology</i> , 2017, 88, 919-919.	1.5	2
116	IgLON5 autoimmunity tested negative in patients with progressive supranuclear palsy and corticobasal syndrome. <i>Parkinsonism and Related Disorders</i> , 2017, 38, 102-103.	1.1	18
117	Consistency of Probable RBD Diagnosis with the RBD Screening Questionnaire: A Follow-up Study. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 403-405.	0.8	20
118	Very late-onset pure autonomic failure. <i>Movement Disorders</i> , 2017, 32, 1106-1108.	2.2	4
119	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017, 32, 853-864.	2.2	1,402
120	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. <i>Lancet Neurology</i> , The, 2017, 16, 701-711.	4.9	248
121	Magnetic resonance imaging for the diagnosis of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2017, 124, 915-964.	1.4	178
122	Parkinson disease. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17013.	18.1	3,048
123	The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward. <i>Movement Disorders</i> , 2017, 32, 510-525.	2.2	92
124	Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. <i>Annals of Neurology</i> , 2017, 82, 419-428.	2.8	161
125	Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study. <i>Movement Disorders</i> , 2017, 32, 1457-1464.	2.2	60
126	Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues. <i>Journal of Neural Transmission</i> , 2017, 124, 1029-1036.	1.4	18

#	ARTICLE	IF	CITATIONS
127	Insulin signalling: new target for Parkinson's treatments?. <i>Lancet, The</i> , 2017, 390, 1628-1630.	6.3	4
128	Brain structural profile of multiple system atrophy patients with cognitive impairment. <i>Journal of Neural Transmission</i> , 2017, 124, 293-302.	1.4	46
129	Topography of Dopamine Transporter Availability in the Cerebellar Variant of Multiple System Atrophy. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 389-396.	0.8	4
130	Diffusion-weighted MRI distinguishes Parkinson disease from the parkinsonian variant of multiple system atrophy: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0189897.	1.1	44
131	Haste makes waste: Decision making in patients with restless legs syndrome with and without augmentation. <i>PLoS ONE</i> , 2017, 12, e0174793.	1.1	14
132	Elastic Abdominal Binders Attenuate Orthostatic Hypotension in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 156-160.	0.8	35
133	Clinical Heterogeneity in Cerebral Hemiatrophy Syndromes. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 382-388.	0.8	5
134	Substantia nigra hyperechogenicity and Parkinson's disease risk in patients with essential tremor. <i>Movement Disorders</i> , 2016, 31, 579-583.	2.2	17
135	Toward disease modification in multiple system atrophy: Pitfalls, bottlenecks, and possible remedies. <i>Movement Disorders</i> , 2016, 31, 235-240.	2.2	9
136	Prodromal Parkinson's disease as defined per MDS research criteria in the general elderly community. <i>Movement Disorders</i> , 2016, 31, 1405-1408.	2.2	71
137	Loss of dorsolateral nigral hyperintensity on 3.0 tesla susceptibility-weighted imaging in idiopathic rapid eye movement sleep behavior disorder. <i>Annals of Neurology</i> , 2016, 79, 1026-1030.	2.8	90
138	Minimally clinically important decline in the parkinsonian variant of multiple system atrophy. <i>Movement Disorders</i> , 2016, 31, 1577-1581.	2.2	14
139	Augmentation and impulsive behaviors in restless legs syndrome: Coexistence or association?. <i>Neurology</i> , 2016, 87, 2603-2603.	1.5	1
140	Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism. <i>Neurology</i> , 2016, 86, 1242-1249.	1.5	89
141	Optimizing odor identification testing as quick and accurate diagnostic tool for Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1408-1413.	2.2	55
142	1.5 Versus 3 tesla magnetic resonance planimetry in neurodegenerative parkinsonism. <i>Movement Disorders</i> , 2016, 31, 1925-1927.	2.2	8
143	Genome-wide association study in essential tremor identifies three new loci. <i>Brain</i> , 2016, 139, 3163-3169.	3.7	78
144	Utility of Nigral Signal Intensity Changes on MR Images to Differentiate Drug-induced Parkinsonism from Parkinson Disease. <i>Radiology</i> , 2016, 281, 651-652.	3.6	1

#	ARTICLE	IF	CITATIONS
145	Reply to letter: Nonmotor symptoms in subjects without evidence of dopaminergic deficits. <i>Movement Disorders</i> , 2016, 31, 1588-1589.	2.2	0
146	Augmentation and impulsive behaviors in restless legs syndrome. <i>Neurology</i> , 2016, 87, 36-40.	1.5	38
147	The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. <i>Journal of Neural Transmission</i> , 2016, 123, 439-445.	1.4	32
148	The Concept of Prodromal Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 681-697.	1.5	195
149	Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. <i>Movement Disorders</i> , 2015, 30, 1885-1892.	2.2	52
150	Plasma fasting cholesterol profiles and age at onset in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1974-1975.	2.2	7
151	Probable RBD and association with neurodegenerative disease markers: A population-based study. <i>Movement Disorders</i> , 2015, 30, 1417-1421.	2.2	86
152	Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism. <i>Movement Disorders</i> , 2015, 30, 1068-1076.	2.2	125
153	Nonmotor symptoms in subjects without evidence of dopaminergic deficits. <i>Movement Disorders</i> , 2015, 30, 976-981.	2.2	32
154	Invasive Treatment Strategies in a Patient with PARK-15 Associated Parkinsonism. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 434-435.	0.8	1
155	Potential of Diffusion Tensor Imaging and Relaxometry for the Detection of Specific Pathological Alterations in Parkinson's Disease (PD). <i>PLoS ONE</i> , 2015, 10, e0145493.	1.1	14
156	Diagnostic value of the REM sleep behavior disorder screening questionnaire in Parkinson's disease. <i>Sleep Medicine</i> , 2015, 16, 186-189.	0.8	86
157	Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD. <i>Neurology</i> , 2015, 84, 654-658.	1.5	164
158	Predictors for mild parkinsonian signs: A prospective population-based study. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 321-324.	1.1	27
159	Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2015, 14, 145-152.	4.9	90
160	Cause-specific mortality in adult epilepsy patients from Tyrol, Austria: hospital-based study. <i>Journal of Neurology</i> , 2015, 262, 126-133.	1.8	59
161	Mortality in Parkinson's disease: A 38-year follow-up study. <i>Movement Disorders</i> , 2015, 30, 266-269.	2.2	95
162	Enteric nervous system α -synuclein immunoreactivity in idiopathic REM sleep behavior disorder. <i>Neurology</i> , 2015, 85, 1761-1768.	1.5	121

#	ARTICLE	IF	CITATIONS
163	Alpha-synuclein immunoreactivity patterns in the enteric nervous system. <i>Neuroscience Letters</i> , 2015, 602, 145-149.	1.0	40
164	Motoric cognitive risk syndrome: Multicenter incidence study. <i>Neurology</i> , 2015, 85, 388-389.	1.5	7
165	The onset of nonmotor symptoms in Parkinson's disease (The ONSET PD Study). <i>Movement Disorders</i> , 2015, 30, 229-237.	2.2	402
166	Three new cases of late-onset cblC defect and review of the literature illustrating when to consider inborn errors of metabolism beyond infancy. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 161.	1.2	96
167	Perimenstrual Fluctuations in Two Siblings With Early-Onset Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 125-127.	0.8	3
168	Visualization of nigrosome 1 and its loss in PD: Pathoanatomical correlation and in vivo 7T MRI. <i>Neurology</i> , 2014, 82, 1752-1752.	1.5	32
169	Towards translational therapies for multiple system atrophy. <i>Progress in Neurobiology</i> , 2014, 118, 19-35.	2.8	35
170	Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group. <i>Movement Disorders</i> , 2014, 29, 857-867.	2.2	193
171	Risk factors and prodromal markers and the development of Parkinson's disease. <i>Journal of Neurology</i> , 2014, 261, 180-187.	1.8	38
172	Relevance of EARLYSTIM in a tertiary movement disorders center. <i>Movement Disorders</i> , 2014, 29, 1220-1221.	2.2	5
173	Multiple system atrophy as emerging template for accelerated drug discovery in α -synucleinopathies. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 793-799.	1.1	18
174	Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder. <i>Movement Disorders</i> , 2014, 29, 1774-1780.	2.2	74
175	Update on diffusion MRI in Parkinson's disease and atypical parkinsonism. <i>Journal of the Neurological Sciences</i> , 2013, 332, 21-29.	0.3	46
176	The natural history of multiple system atrophy: a prospective European cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 264-274.	4.9	426
177	Nonmotor symptoms in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 581-583.	1.4	15
178	Structural MRI in Idiopathic Parkinson Disease and Parkinsonism. , 2013, , 105-128.		2
179	Substantia Nigra Hyperechogenicity as a Marker for Parkinson's Disease: A Population-Based Study. <i>Neurodegenerative Diseases</i> , 2013, 12, 212-218.	0.8	28
180	Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease. <i>Brain</i> , 2013, 136, 3028-3037.	3.7	52

#	ARTICLE	IF	CITATIONS
181	Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's disease. <i>International Clinical Psychopharmacology</i> , 2013, 28, 1.	0.9	12
182	Cause-specific mortality among patients with epilepsy: Results from a 30-year cohort study. <i>Epilepsia</i> , 2013, 54, 495-501.	2.6	82
183	Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 216-219.	2.2	112
184	Which dyskinesia scale best detects treatment response?. <i>Movement Disorders</i> , 2013, 28, 341-346.	2.2	76
185	Prevalence and Burden of Gait Disorders in Elderly Men and Women Aged 60-97 Years: A Population-Based Study. <i>PLoS ONE</i> , 2013, 8, e69627.	1.1	151
186	The Unified Multiple System Atrophy Rating Scale: Intrarater reliability. <i>Movement Disorders</i> , 2012, 27, 1683-1685.	2.2	18
187	Left hemispheric predominance of nigrostriatal dysfunction in Parkinson's disease. <i>Brain</i> , 2012, 135, 3348-3354.	3.7	95
188	An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes. <i>Proteome Science</i> , 2012, 10, 71.	0.7	22
189	Drug safety evaluation of rotigotine. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 503-512.	1.0	17
190	Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease. <i>Clinical Interventions in Aging</i> , 2012, 7, 83.	1.3	13
191	White and Gray Matter Abnormalities in Narcolepsy with Cataplexy. <i>Sleep</i> , 2012, 35, 345-351.	0.6	46
192	Deep brain stimulation in Huntington's disease: A 4-year follow-up case report. <i>Movement Disorders</i> , 2012, 27, 806-807.	2.2	29
193	Neuroimaging: Current role in detecting pre-motor Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 634-643.	2.2	26
194	Is transcranial sonography useful to distinguish drug-induced parkinsonism from Parkinson's disease?. <i>Movement Disorders</i> , 2012, 27, 1194-1196.	2.2	17
195	A follow-up study of substantia nigra echogenicity in healthy adults. <i>Movement Disorders</i> , 2012, 27, 1196-1197.	2.2	17
196	Is transcranial sonography useful to distinguish scans without evidence of dopaminergic deficit patients from Parkinson's disease?. <i>Movement Disorders</i> , 2012, 27, 1182-1185.	2.2	32
197	Orthostatic Hypotension Is Differentially Associated with the Cerebellar Versus the Parkinsonian Variant of Multiple System Atrophy: a Comparative Study. <i>Cerebellum</i> , 2012, 11, 223-226.	1.4	22
198	Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]125I-CIT SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1012-1020.	3.3	40

#	ARTICLE	IF	CITATIONS
199	Substantia nigra hypoechogenicity in Friedreich ataxia. <i>Movement Disorders</i> , 2012, 27, 332-333.	2.2	5
200	Video-EEG monitoring: Safety and adverse events in 507 consecutive patients. <i>Epilepsia</i> , 2011, 52, 443-452.	2.6	82
201	INTENSIVE CARE MANAGEMENT IN VERY OLD ADULTS: TWO CASES WITH CLOSTRIDIUM TETANI INFECTION. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 552-553.	1.3	3
202	Pramipexole extended release in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1229-1234.	1.4	6
203	A Mutation in VPS35, Encoding a Subunit of the Retromer Complex, Causes Late-Onset Parkinson Disease. <i>American Journal of Human Genetics</i> , 2011, 89, 168-175.	2.6	757
204	A novel computer-assisted image analysis of [123I]β-CIT SPECT images improves the diagnostic accuracy of parkinsonian disorders. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 702-710.	3.3	27
205	Axial myopathy in parkinsonism. <i>Movement Disorders</i> , 2011, 26, 1569-1571.	2.2	6
206	The influence of deep brain stimulation on pain perception in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1367-1368.	2.2	26
207	The role of arterial spin labeling, a noninvasive MRI perfusion method, in identifying an abnormal cerebral perfusion pattern in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1197-1197.	2.2	1
208	The <i>Movement</i> Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, S2-41.	2.2	479
209	The <i>Movement</i> Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, S42-80.	2.2	863
210	White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: A diffusion-tensor imaging and voxel-based morphometry study. <i>Annals of Neurology</i> , 2011, 69, 400-407.	2.8	203
211	Enlarged Substantia Nigra Hyperechogenicity and Risk for Parkinson Disease. <i>Archives of Neurology</i> , 2011, 68, 932.	4.9	146
212	Significance of MRI in Diagnosis and Differential Diagnosis of Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2010, 7, 300-318.	0.8	116
213	Social and clinical determinants of quality of life in Parkinson's disease in Austria: a cohort study. <i>Journal of Neurology</i> , 2010, 257, 638-645.	1.8	53
214	Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. <i>Lancet Neurology</i> , The, 2010, 9, 1070-1077.	4.9	349
215	Minocycline 1-year therapy in multiple system atrophy: Effect on clinical symptoms and [¹¹ C]-(R)-β-PK11195 PET (MEMSA trial). <i>Movement Disorders</i> , 2010, 25, 97-107.	2.2	163
216	Mortality in Parkinson's disease, a 20-year follow-up study. <i>Movement Disorders</i> , 2010, 25, 661-662.	2.2	41

#	ARTICLE	IF	CITATIONS
217	Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1357-1363.	2.2	159
218	Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly. <i>Movement Disorders</i> , 2010, 25, 1464-1469.	2.2	45
219	Reply: "Restless Legs Syndrome and Parkinson's Disease". <i>Movement Disorders</i> , 2010, 25, 1314-1315.	2.2	0
220	Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry. <i>Movement Disorders</i> , 2010, 25, 2604-2612.	2.2	205
221	Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain-to-pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy. <i>Movement Disorders</i> , 2010, 25, 2444-2449.	2.2	74
222	Multiple System Atrophy. <i>Blue Books of Neurology</i> , 2010, 34, 340-359.	0.1	0
223	Brain Magnetic Resonance Imaging Techniques in the Diagnosis of Parkinsonian Syndromes. <i>Neuroimaging Clinics of North America</i> , 2010, 20, 29-55.	0.5	91
224	Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. <i>Movement Disorders</i> , 2009, 24, 949-964.	2.2	145
225	Mortality in Parkinson's disease: A 20-year follow-up study. <i>Movement Disorders</i> , 2009, 24, 819-825.	2.2	108
226	Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder. <i>Movement Disorders</i> , 2009, 24, 1906-1909.	2.2	91
227	Potential of advanced MR imaging techniques in the differential diagnosis of parkinsonism. <i>Movement Disorders</i> , 2009, 24, S711-20.	2.2	49
228	Restless legs syndrome in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 2076-2080.	2.2	111
229	Red flags for multiple system atrophy. <i>Movement Disorders</i> , 2008, 23, 1093-1099.	2.2	215
230	Managing the Non-Motor Symptoms of Parkinson's Disease. , 2008, , 91-120.		2
231	Predictors of Survival in Dementia with Lewy Bodies and Parkinson Dementia. <i>Neurodegenerative Diseases</i> , 2007, 4, 428-430.	0.8	72
232	Dementia with Lewy bodies and Parkinson disease with dementia: Can MRI make the difference?. <i>Neurology</i> , 2007, 69, 717-718.	1.5	6
233	Soluble Receptor Activator of Nuclear Factor- κ B Ligand and Risk for Cardiovascular Disease. <i>Circulation</i> , 2007, 116, 385-391.	1.6	148
234	MRI for the differential diagnosis of neurodegenerative parkinsonism in clinical practice. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S400-S405.	1.1	26

#	ARTICLE	IF	CITATIONS
235	Abnormal responses to repetitive transcranial magnetic stimulation in multiple system atrophy. <i>Movement Disorders</i> , 2007, 22, 174-178.	2.2	10
236	An open trial of levetiracetam for segmental and generalized dystonia. <i>Movement Disorders</i> , 2007, 22, 1649-1651.	2.2	38
237	Diffusion weighted imaging best discriminates PD from MSA-P: A comparison with tilt table testing and heart MIBG scintigraphy. <i>Movement Disorders</i> , 2007, 22, 1771-1776.	2.2	92
238	Voxel based morphometry reveals specific gray matter changes in primary dystonia. <i>Movement Disorders</i> , 2007, 22, 1538-1542.	2.2	121
239	Cerebrospinal fluid hypocretin levels in multiple system atrophy. <i>Movement Disorders</i> , 2007, 22, 1822-1824.	2.2	34
240	Differentiation of SCA2 from MSA-C using proton magnetic resonance spectroscopic imaging. <i>Journal of Magnetic Resonance Imaging</i> , 2007, 25, 564-569.	1.9	38
241	Progression of brain atrophy in multiple system atrophy. <i>Journal of Neurology</i> , 2007, 254, 191-196.	1.8	108
242	Progression of putaminal degeneration in multiple system atrophy: A serial diffusion MR study. <i>NeuroImage</i> , 2006, 31, 240-245.	2.1	98
243	Parkinson's disease and arithmetics: The role of executive functions. <i>Journal of the Neurological Sciences</i> , 2006, 248, 124-130.	0.3	32
244	Topography of Dopamine Transporter Availability in Progressive Supranuclear Palsy. <i>Archives of Neurology</i> , 2006, 63, 1154.	4.9	59
245	Genetic analysis of candidate genes modifying the age-at-onset in Huntington's disease. <i>Human Genetics</i> , 2006, 120, 285-292.	1.8	39
246	Topography of cerebral monoamine transporter availability in families with SCA2 mutations: a voxel-wise [¹²³ I]β-CIT SPECT analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 1084-1090.	3.3	2
247	Seminar on choreas. <i>Lancet Neurology</i> , The, 2006, 5, 589-602.	4.9	282
248	Cortical atrophy in the cerebellar variant of multiple system atrophy: A voxel-based morphometry study. <i>Movement Disorders</i> , 2006, 21, 159-165.	2.2	67
249	Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA Study Group (EMSA SG). <i>Movement Disorders</i> , 2006, 21, 179-186.	2.2	126
250	Health-related quality of life in multiple system atrophy. <i>Movement Disorders</i> , 2006, 21, 809-815.	2.2	102
251	Topography of putaminal degeneration in multiple system atrophy: A diffusion magnetic resonance study. <i>Movement Disorders</i> , 2006, 21, 847-852.	2.2	62
252	Diffusion-weighted imaging in Huntington's disease. <i>Movement Disorders</i> , 2006, 21, 1043-1047.	2.2	41

#	ARTICLE	IF	CITATIONS
253	Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study. <i>Movement Disorders</i> , 2006, 21, 1109-1113.	2.2	82
254	Levodopa-induced sleepiness in the Parkinson variant of multiple system atrophy. <i>Movement Disorders</i> , 2006, 21, 1281-1283.	2.2	27
255	Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. <i>Brain</i> , 2006, 129, 538-542.	3.7	120
256	An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism. <i>Current Opinion in Neurology</i> , 2005, 18, 370-375.	1.8	92
257	Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population. <i>European Heart Journal</i> , 2005, 26, 279-287.	1.0	60
258	Treatment of dementia in Parkinson's disease. <i>The Cochrane Library</i> , 2005, , .	1.5	0
259	Computerized Tremor Analysis of Valproate-induced Tremor: A Comparative Study of Controlled-release versus Conventional Valproate. <i>Epilepsia</i> , 2005, 46, 320-323.	2.6	37
260	Prevalence of movement disorders in men and women aged 50â€“89 years (Bruneck Study cohort): a population-based study. <i>Lancet Neurology</i> , The, 2005, 4, 815-820.	4.9	271
261	Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. <i>Annals of Neurology</i> , 2005, 58, 630-634.	2.8	193
262	Grading of neuropathology in multiple system atrophy: Proposal for a novel scale. <i>Movement Disorders</i> , 2005, 20, S29-S36.	2.2	161
263	Progression of parkinsonism in multiple system atrophy. <i>Journal of Neurology</i> , 2005, 252, 91-96.	1.8	55
264	Voxel-wise analysis of [123I]Î²-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. <i>Brain</i> , 2005, 128, 1605-1612.	3.7	115
265	Treatment of psychosis in Parkinson's disease. <i>The Cochrane Library</i> , 2005, , .	1.5	0
266	Abnormalities of dopaminergic neurotransmission in SCA2: A combined 123I-Î²CIT and 123I-IBZM SPECT study. <i>Movement Disorders</i> , 2004, 19, 1320-1325.	2.2	37
267	Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. <i>Movement Disorders</i> , 2004, 19, 1438-1445.	2.2	86
268	Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). <i>Movement Disorders</i> , 2004, 19, 1391-1402.	2.2	481
269	Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. <i>NeuroImage</i> , 2004, 21, 1443-1451.	2.1	149
270	Basal forebrain atrophy is a distinctive pattern in dementia with Lewy bodies. <i>NeuroReport</i> , 2004, 15, 1711-1714.	0.6	40

#	ARTICLE	IF	CITATIONS
271	Clinical and neuropathological correlates of Lewy body disease. <i>Acta Neuropathologica</i> , 2003, 106, 188-189.	3.9	15
272	Increased daytime sleepiness in Parkinson's disease: A questionnaire survey. <i>Movement Disorders</i> , 2003, 18, 319-323.	2.2	70
273	Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. <i>Movement Disorders</i> , 2003, 18, 1132-1138.	2.2	153
274	Auditory startle response in cervical dystonia. <i>Movement Disorders</i> , 2003, 18, 1522-1526.	2.2	25
275	Exaggerated auditory startle responses in multiple system atrophy: a comparative study of parkinson and cerebellar subtypes. <i>Clinical Neurophysiology</i> , 2003, 114, 541-547.	0.7	29
276	Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy. <i>NeuroImage</i> , 2003, 20, 1253-1263.	2.1	30
277	Neuropathologic Changes in Parkinson Disease With Late Onset of Dementia. <i>Archives of Neurology</i> , 2003, 60, 452.	4.9	7
278	Differentiation of Malignant and Benign Musculoskeletal Tumors: Combined Color and Power Doppler US and Spectral Wave Analysis. <i>Radiology</i> , 2002, 223, 410-416.	3.6	141
279	Lewy bodies in patients presenting clinically with Alzheimer disease. <i>Journal of Alzheimer's Disease</i> , 2002, 4, 327-328.	1.2	3
280	Freezing of gait in postmortem-confirmed atypical parkinsonism. <i>Movement Disorders</i> , 2002, 17, 1041-1045.	2.2	46
281	Riluzole therapy in cervical dystonia. <i>Movement Disorders</i> , 2002, 17, 198-200.	2.2	28
282	Polycystic ovaries, obesity and insulin resistance in women with epilepsy. <i>Journal of Neurology</i> , 2002, 249, 835-841.	1.8	89
283	Riluzole in Huntington's disease (HD): an open label study with one year follow up. <i>Journal of Neurology</i> , 2001, 248, 866-869.	1.8	71
284	Irresistible onset of sleep during acute levodopa challenge in a patient with multiple system atrophy (MSA): Placebo-controlled, polysomnographic case report. <i>Movement Disorders</i> , 2001, 16, 1177-1179.	2.2	19
285	Overstimulation of the α_1 -adrenergic receptor causes a seizure plus syndrome. <i>Nature Medicine</i> , 2001, 7, 132-132.	15.2	5
286	Failure of Neuroprotection by Embryonic Striatal Grafts in a Double Lesion Rat Model of Striatonigral Degeneration (Multiple System Atrophy). <i>Experimental Neurology</i> , 2000, 164, 166-175.	2.0	16
287	In Vivo Magnetic Resonance Imaging of Embryonic Neural Grafts in a Rat Model of Striatonigral Degeneration (Multiple System Atrophy). <i>NeuroImage</i> , 2000, 12, 209-218.	2.1	12
288	Magnetic resonance imaging of multiple system atrophy. , 0, , 167-203.		0

#	ARTICLE	IF	CITATIONS
289	Hospital Admissions of Huntington's Disease patients in a Huntington's Disease centre between 2011 and 2016: a retrospective analysis. <i>Movement Disorders Clinical Practice</i> , 0, , .	0.8	0